Literature DB >> 16332474

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival.

Taylor S Riall1, John L Cameron, Keith D Lillemoe, Kurtis A Campbell, Patricia K Sauter, JoAnn Coleman, Ross A Abrams, Daniel Laheru, Ralph H Hruban, Charles J Yeo.   

Abstract

The study objective was to update the survival analysis at the 5-year mark of patients undergoing standard versus radical (extended) pancreaticoduodenectomy (PD) for periampullary adenocarcinoma (cancers of the pancreas, ampulla, common bile duct, and duodenum). A prospective randomized trial was performed (April 1996 through June 2001) comparing survival after pylorus-preserving PD resection (standard) to survival after PD with distal gastrectomy and retroperitoneal lymphadenectomy (radical). An interim report (Ann Surg 1999;229:613) and report after closing the trial (Ann Surg 2002;236:355) showed no differences in survival between the standard and radical groups. Two hundred ninety-nine patients were randomized to either the standard or radical group. Five patients were excluded from final analysis because final pathology failed to reveal adenocarcinoma. The 5-year survival of the two groups was evaluated. The median live patient follow-up is now 64 months (5.33 years). For all periampullary cancer patients, those undergoing standard resection had 1- and 5-year survival rates of 78% and 25%, respectively, compared with 76% and 31% (P = 0.57) for those patients in the radical group. For pancreatic adenocarcinoma patients, the 1- and 5-year survival rates in the standard group were 75% and 13%, respectively, compared with 73% and 29% in the radical group (P = 0.13). The increased morbidity rate, longer operative time, and similar survival for radical PD led us to conclude that pylorus-preserving PD without retroperitoneal lymphadenectomy should be the procedure of choice for most patients with resectable periampullary adenocarcinoma. While there is an intriguing trend toward improved survival in patients with pancreatic adenocarcinoma in the radical group, this trend may be largely accounted for by the higher incidence of microscopically margin positive resections in the standard resection group (21%) compared with a 5% incidence in the radical group (P = 0.002).

Entities:  

Mesh:

Year:  2005        PMID: 16332474     DOI: 10.1016/j.gassur.2005.08.034

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  32 in total

1.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

2.  Randomized prospective trial of pylorus-preserving vs. Classic duodenopancreatectomy (Whipple procedure): initial clinical results.

Authors:  C A Seiler; M Wagner; C Sadowski; C Kulli; M W Büchler
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

3.  Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors.

Authors:  Khe T C Tran; Hans G Smeenk; Casper H J van Eijck; Geert Kazemier; Wim C Hop; Jan Willem G Greve; Onno T Terpstra; Jan A Zijlstra; Piet Klinkert; Hans Jeekel
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

Review 4.  DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma.

Authors:  D C Allison; S Piantadosi; R H Hruban; W C Dooley; E K Fishman; C J Yeo; K D Lillemoe; H A Pitt; P Lin; J L Cameron
Journal:  J Surg Oncol       Date:  1998-03       Impact factor: 3.454

5.  Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection.

Authors:  R Delcore; F J Rodriguez; J Forster; A S Hermreck; J H Thomas
Journal:  Am J Surg       Date:  1996-11       Impact factor: 2.565

6.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

7.  Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

Authors:  R J Geer; M F Brennan
Journal:  Am J Surg       Date:  1993-01       Impact factor: 2.565

Review 8.  Prognostic factors in ductal pancreatic cancer.

Authors:  C J Yeo; J L Cameron
Journal:  Langenbecks Arch Surg       Date:  1998-04       Impact factor: 3.445

9.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  C J Yeo; T A Sohn; J L Cameron; R H Hruban; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

10.  Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion.

Authors:  M Kayahara; T Nagakawa; K Ueno; T Ohta; Y Tsukioka; I Miyazaki
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

View more
  63 in total

1.  Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.

Authors:  Hisashi Imai; Ryuichiro Doi; Hiroyuki Kanazawa; Naoko Kamo; Masayuki Koizumi; Toshihiko Masui; Yasuhiro Iwanaga; Yoshiya Kawaguchi; Yasutsugu Takada; Hiroyoshi Isoda; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

2.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 3.  Diffusion-weighted imaging of pancreatic cancer.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Flavia Dal Corso; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Radiol       Date:  2015-10-28

Review 4.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

5.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

6.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

7.  Hospital readmission after pancreaticoduodenectomy.

Authors:  Dawn M Emick; Taylor S Riall; John L Cameron; Jordan M Winter; Keith D Lillemoe; Joann Coleman; Patricia K Sauter; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

8.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

9.  [Total pancreatectomy: renaissance of a surgical procedure].

Authors:  T Keck; U T Hopt
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

10.  Impact of total pancreatectomy: short- and long-term assessment.

Authors:  Louise Barbier; Wisam Jamal; Safi Dokmak; Béatrice Aussilhou; Olivier Corcos; Philippe Ruszniewski; Jacques Belghiti; Alain Sauvanet
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.